Sanofi builds on immunology alliance with Regeneron for $1B upfront

Summary

Sanofi is expanding its antibody collaboration with Regeneron with a $1 billion upfront payment as the Dupixent patent cliff approaches. The deal builds on the existing partnership that created the immunology megablockbuster.